Scope
NICE CG150 addresses primary headache disorders in people aged 12 and older, with assessment for secondary causes before treatment. Management differs for tension-type headache, migraine and cluster headache, and medication overuse must be recognized. The captured guidance includes recent preventive-treatment review rules and links to technology appraisals. Drug selection requires attention to age, pregnancy, comorbidities and the relevant product information.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Identify secondary-headache concerns and track symptoms
- Evaluate and consider investigation or referral for worsening headache with fever, sudden maximum intensity within 5 minutes, new neurological or cognitive change, altered consciousness, recent head trauma, exertional or postural triggers, giant-cell-arteritis or acute-glaucoma features, or a substantial change in pattern. [1]
- New headache with immunocompromise, relevant malignancy history or unexplained vomiting warrants consideration of investigation or referral. Do not request neuroimaging solely for reassurance in an established primary headache or medication-overuse diagnosis. [1]
- Consider a diary for at least 8 weeks recording frequency, duration, severity, associated symptoms, all acute medicines, possible triggers and menstrual relationship. Use it to monitor treatment and discuss impact. [1]
- Typical aura symptoms are fully reversible, develop gradually over at least 5 minutes and last 5–60 minutes; they may be visual, sensory or speech symptoms with or without headache. Motor weakness, diplopia, monocular visual symptoms, poor balance or reduced consciousness require consideration of further investigation or referral. [1]
- Chronic migraine means headache on at least 15 days per month, including at least 8 with migraine features, for more than 3 months. Suspect medication overuse when headache develops or worsens during at least 3 months of triptans, opioids, ergots or combination analgesics on at least 10 days/month, or simple analgesics/NSAIDs on at least 15 days/month. [1]
Treat tension-type headache without opioids
- Consider paracetamol, an NSAID or aspirin for acute tension-type headache according to preference and risks, but do not offer aspirin below age 16. Do not use opioids. For chronic tension-type prevention, consider up to 10 acupuncture sessions over 5–8 weeks. [1]
Select an acute migraine regimen and route
- Offer an oral triptan with an NSAID or paracetamol, considering preference, comorbidities and adverse effects. At ages 12–17, consider a nasal triptan rather than an oral preparation. [1]
- For someone preferring one drug, consider an oral triptan, NSAID, aspirin 900 mg or paracetamol, subject to individual risk. Aspirin must not be offered below 16; for ages 12–17 consider a nasal triptan. If one triptan is consistently ineffective, try another. [1]
- Consider an antiemetic even without nausea. When oral treatment, or nasal treatment in young people, is ineffective or intolerable, consider non-oral metoclopramide or prochlorperazine and adding a non-oral NSAID or triptan if not already tried, accounting for product warnings and precautions. [1]
- For adults, the captured guideline links acute oral CGRP treatment to atogepant or rimegepant appraisals only after at least 2 triptans have failed, or when triptans are contraindicated or intolerable and NSAIDs plus paracetamol have also been insufficient. Do not use ergots or opioids for acute migraine. [1]
Choose prevention jointly and review response
- Consider propranolol, topiramate or amitriptyline after discussing suitability, benefits and harms. If one fails or is intolerable, discuss the remaining options unless unsafe. Consider propranolol overdose risk in people with depression and safe antidepressant prescribing and withdrawal with amitriptyline. [1]
- Do not use topiramate for migraine prevention in pregnancy. In women who could become pregnant, use it only when the Pregnancy Prevention Programme requirements, including highly effective contraception, are fulfilled. [1]
- Do not offer gabapentin for migraine prevention. If propranolol, topiramate and amitriptyline fail, are intolerable or unsuitable, consider up to 10 acupuncture sessions over 5–8 weeks. Continue an existing effective preventive when appropriate and review the need for prophylaxis after 3–6 months. [1]
- For adults with at least 4 migraine days/month after at least 3 preventive medicines have failed, been intolerable or unsuitable, NICE links to CGRP prevention appraisals for atogepant, eptinezumab, fremanezumab, erenumab and galcanezumab. The erenumab listing specifies 140 mg; complete appraisal conditions still apply. [1]
- Rimegepant prevention is an option for episodic migraine in adults with at least 4 but fewer than 15 attacks/month after at least 3 preventive medicines have failed, been intolerable or unsuitable. Botulinum toxin A is an option for chronic migraine after the same preventive failures only when medication overuse is appropriately managed. [1]
- Stop a preventive CGRP inhibitor after 12 weeks if migraine frequency has not fallen by at least 50% for episodic or 30% for chronic migraine. Stop botulinum toxin A if headache days fall by less than 30% after 2 cycles, or the condition becomes episodic for 3 consecutive months. [1]
Apply reproductive and pregnancy precautions
- Suspect menstrual-related migraine when attacks predominate from 2 days before to 3 days after menstruation starts in at least 2 of 3 cycles; confirm with a diary over at least 2 cycles. If predictable attacks resist usual acute care, consider frovatriptan 2.5 mg twice daily or zolmitriptan 2.5 mg twice or three times daily on expected attack days. [1]
- Do not routinely offer combined hormonal contraception in migraine with aura. For acute migraine during pregnancy, offer paracetamol; consider a triptan or NSAID only after discussing pregnancy-specific risks, including the linked warning about prolonged NSAID use after 20 weeks. Seek specialist advice for prevention during pregnancy. [1]
Use cluster-specific acute and preventive treatment
- Discuss imaging for the first cluster bout with an appropriately experienced GP or neurologist. Offer oxygen and/or a subcutaneous or nasal triptan for acute attacks; oxygen should be 100% at at least 12 L/min through a non-rebreathing mask with reservoir, with home and ambulatory provision. [1]
- For cluster attacks, do not use paracetamol, NSAIDs, opioids, ergots or oral triptans. Consider verapamil during a bout; seek specialist guidance including ECG monitoring if unfamiliar with its use, and specialist care if it fails or treatment is needed during pregnancy. [1]
Plan withdrawal with support and appropriate referral
- Explain that medication-overuse headache is treated by withdrawing the overused medicine. The general headache guidance advises stopping overused acute medicines for at least 1 month; opioid withdrawal requires its separate dependence guidance, and strong-opioid use warrants consideration of specialist or inpatient support. [1]
- Warn that headache may initially worsen and withdrawal symptoms can occur; provide close support. Consider prevention for the underlying primary disorder. Inpatient withdrawal is not routine, but relevant comorbidity or repeated failed attempts can justify specialist/inpatient care. Reassess the diagnosis and plan after 4–8 weeks. [1]
Limitations and use
- This summary does not reproduce every headache-feature table or every secondary-headache investigation pathway. Red-flag assessment and a new change in symptoms still require clinical evaluation.
- CGRP and botulinum options are linked UK appraisal pathways with additional conditions, not complete prescriptions or confirmation of local Indian availability. Full doses, contraindications and pregnancy precautions require the relevant product and specialist guidance.
- The source identifies several adolescent triptan, preventive and menstrual-migraine uses as off-label. Its general medication-overuse advice must not be treated as a universal abrupt opioid-withdrawal instruction.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Headaches in over 12s: diagnosis and management
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 19 September 2012
- Publisher’s latest update
- 3 June 2025
- Resource type
- Clinical guideline · House clinical summary
Earlier House summaries: primary headache disorders nice
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.